RA Capital Management - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.

Quarter-by-quarter ownership
RA Capital Management ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q1 2019$70,492,000
-18.1%
8,659,983
-18.8%
3.04%
-39.3%
Q4 2018$86,029,000
+22.1%
10,660,349
+15.4%
5.01%
+32.9%
Q3 2018$70,461,000
+76.1%
9,234,692
+32.2%
3.77%
+45.0%
Q2 2018$40,022,000
+20.1%
6,984,6920.0%2.60%
+1.8%
Q1 2018$33,317,000
-2.9%
6,984,6920.0%2.55%
-11.0%
Q4 2017$34,295,000
-6.3%
6,984,6920.0%2.87%
-13.2%
Q3 2017$36,600,000
+27.5%
6,984,692
+35.3%
3.31%
+0.4%
Q2 2017$28,702,000
-2.1%
5,162,242
+47.9%
3.29%
-8.4%
Q1 2017$29,314,000
+54.9%
3,489,795
+16.7%
3.60%
+34.1%
Q4 2016$18,925,000
+43.5%
2,989,7950.0%2.68%
+97.1%
Q3 2016$13,185,000
+55.3%
2,989,7950.0%1.36%
+15.6%
Q2 2016$8,491,000
+0.4%
2,989,7950.0%1.18%
+8.8%
Q1 2016$8,461,000
-73.5%
2,989,795
-3.4%
1.08%
-65.8%
Q4 2015$31,931,000
+134.1%
3,094,064
+158.6%
3.16%
+61.3%
Q3 2015$13,641,000
-64.9%
1,196,603
-54.1%
1.96%
-49.9%
Q2 2015$38,898,000
-37.8%
2,605,361
-62.4%
3.91%
-37.0%
Q1 2015$62,547,000
-27.0%
6,926,617
-1.8%
6.21%
-32.6%
Q4 2014$85,732,000
+24.0%
7,050,356
-0.3%
9.21%
+12.8%
Q3 2014$69,136,000
+69.5%
7,069,159
+121.0%
8.17%
+98.2%
Q2 2014$40,781,000
-11.3%
3,198,529
-26.4%
4.12%
+24.9%
Q1 2014$45,996,000
+39.2%
4,347,4560.0%3.30%
-14.3%
Q4 2013$33,041,000
-22.3%
4,347,456
-25.6%
3.85%
-13.3%
Q3 2013$42,549,0005,844,7004.44%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
RP Management, LLC 3,846,154$27,230,77026.28%
Prosight Management, LP 2,408,135$17,049,5965.40%
Kynam Capital Management, LP 3,133,193$22,183,0063.63%
Saturn V Capital Management LP 982,458$6,955,8032.91%
AlphaCentric Advisors LLC 649,000$4,594,9202.61%
TANG CAPITAL MANAGEMENT LLC 1,800,000$12,744,0001.80%
SILVERARC CAPITAL MANAGEMENT, LLC 791,671$5,605,0311.70%
Eversept Partners, LP 2,479,103$17,552,0491.48%
DAFNA Capital Management LLC 652,000$4,616,1601.44%
Avoro Capital Advisors LLC 11,550,000$81,774,0001.28%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders